Thus, targeting of upstream pathways (e.g., inhibiting FLT3 via gilteritinib) in addition to treatment with rapamycin may show less resistance, better anti-tumor effects (Figure 3), and better mobilization of NK cells [111]. This evidence concerns the gene FLT3 and neoplasm.